


AMENDMENTSIN THE CLAIMS

Please rewrite the claims as follows:

37. (Amended) A prodrug comprising a drug moiety bound to a carrier framework having the formula (Z):



wherein:

X= OH, OMe or N(CH<sub>3</sub>)<sub>2</sub>, and  
n=0-3;

and;

R<sub>1</sub>=H, C<sub>1-4</sub> lower alkyl, or together with R<sub>2</sub> forms part of a cycloalkyl group which may be further substituted to form part of a polycyclic cycloalkyl group;

R<sub>2</sub>=H, OMe, C<sub>1-4</sub> lower alkyl, or together with R<sub>1</sub> and/or R<sub>3</sub> forms part of a cycloalkyl, polycyclic cycloalkyl, or forms part of a polycyclic aromatic group by linkage to R<sub>4</sub>;

R<sub>3</sub>=H, OMe, C<sub>1-4</sub> lower alkyl or together with R<sub>2</sub> forms part of a cycloalkyl, polycyclic cycloalkyl; and


R<sub>4</sub>=H or is fused directly to the aromatic position designated by R<sub>2</sub> and either:

the drug moiety is derived from a drug having a free amino, hydroxyl or mercapto group and which links it to the rest of the prodrug, such that A represents NH, NR (R=C<sub>1-4</sub> lower alkyl), O or S; or

the drug moiety is derived from a drug having a carboxylate group, an ester linkage joining it to the rest of the prodrug and A being absent.

42. (Amended) A prodrug according to claim 37 wherein the framework includes a naphthyl group.

45. (Amended) A prodrug according to claim 44, having the general formula (Y):




R<sub>2</sub>, R<sub>3</sub> and X being selected from any one of the group of:

- a) R<sub>2</sub> = H, R<sub>3</sub> = H, X = OMe in Formula XVIII;
- b) R<sub>2</sub> = H, R<sub>3</sub> = OMe, X = OMe in Formula XIX; and
- c) R<sub>2</sub> = OMe, R<sub>3</sub> = H, X = OMe in Formula XXII.

48. A prodrug according to claim 47, having a formula of:

(XXX):




52. (Amended) A method of inhibiting tumor cell growth comprising:

contacting a tumor cell with a prodrug according to any one of claims 37 or 38, wherein

the tumor cell comprises an enzyme having aromatic hydroxylase activity.

57. A prodrug comprising a drug moiety bound to a carrier framework having the formula selected from the group consisting of:

(XXXI):



and

(XXXII):